WYETH SELECTS INGENUITY’S WEB-DELIVERED APPLICATION FOR USE IN BOTH EARLY DISCOVERY AND CLINICAL GENOMICS
Mountain View, California, January 26, 2004 - Ingenuity announced today that Wyeth has purchased IPA for use across the entire drug discovery and development chain from early discovery to clinical phases.
IPA enables biologists to explore, understand, and discover therapeutically relevant networks significant to experiment results. Using a researcher’s gene or protein dataset in conjunction with Ingenuity’s genome-scale biological knowledge base, the application generates multiple biological networks with associated functional analysis to facilitate biological understanding of an experiment.
Frank C. Mara, Senior Vice President at Ingenuity stated, “We are pleased to be working with Wyeth, particularly given Wyeth’s recognized industry leadership in both the genomics and proteomics research fields. And their scope of deployment across the drug discovery and development chain demonstrates broad utility of our systems biology solutions.”
About Ingenuity Systems
Ingenuity Systems is helping life science researchers explore and understand biological systems that are foundational to human health and disease. Ingenuity delivers capabilities and expertise to researchers through analysis software, genome-scale computable network databases, and knowledge management services and infrastructure, resulting in increased productivity and faster drugs to market. The company was founded in 1998 and is headquartered in Mountain View, California.www.ingenuity.com.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.